Download Files:

Dinaciclib

SKU T1912-1 mL * 10 mM (in DMSO) Category Small Compound Brand: TargetMol

Price range: 75 CAD through 619 CAD

For Research Use Only (RUO). This product is sold strictly for laboratory research use. Not for human or veterinary consumption, therapeutic, or diagnostic use.For sale to research organizations and laboratories only; not for patients or for personal use.

Size

2 mg 1 mL * 10 mM (in DMSO)10 mg 5 mg 50 mg

Clear

Products Details

Product Description

– Dinaciclib (SCH 727965) is a selective CDK inhibitor targeting CDK1, CDK2, CDK5, and CDK9 (IC50 = 3/1/1/4 nM). It exhibits potential antitumor activity by inhibiting the incorporation of thoracic glycan (dThd) DNA.

For Research Use Only (RUO). This product is sold strictly for laboratory research use only. Not for human or veterinary consumption, therapeutic, or diagnostic use. Any pharmacological, therapeutic, cosmetic, or biological effects described above are provided as research context only and do not represent intended or approved uses of this product.

Web ID

– T1912

Storage Temperature

– -20℃

Shipping

– Blue Ice

Molecular Formula

– C21H28N6O2

Citations

– 1. Wang Z, Chen D, Guan D, et al. Material properties of phase-separated TFEB condensates regulate the autophagy-lysosome pathway. Journal of Cell Biology. 2022, 221(5): e202112024 2. Zhang G M, Huang S S, Ye L X, et al. Reciprocal positive regulation between BRD4 and YAP in GNAQ-mutant uveal melanoma cells confers sensitivity to BET inhibitors. Pharmacological Research. 2022: 106464. 3. Lin B, Li Y, Wang T, et al. CRMP2 is a therapeutic target that suppresses the aggressiveness of breast cancer cells by stabilizing RECK. Oncogene. 2020, 39(37): 6024-6040 4. Ly T T G, Yun J, Ha J S, et al. Inhibitory Effect of Etravirine, a Non-Nucleoside Reverse Transcriptase Inhibitor, via Anterior Gradient Protein 2 Homolog Degradation against Ovarian Cancer Metastasis. International Journal of Molecular Sciences. 2022, 23(2): 944. 5. Pu Y, Yan D, Tu L, et al. CDK Inhibition Reverses Acquired 5-Fluorouracil Resistance in Hepatocellular Carcinoma Cells. Disease Markers. 2022 6. Jiang L, Yu Y, Li Z, et al.BMS-265246, a Cyclin-Dependent Kinase Inhibitor, Inhibits the Infection of Herpes Simplex Virus Type 1.Viruses.2023, 15(8): 1642. 7. Ye L, Shen S, Mao Q, et al.Nuclear-localized HKDC1 promotes hepatocellular carcinoma through phosphorylating RBBP5 to upregulate H3K4me3.Cell Reports.2025, 44(2).

References

– Feldmann G, et al. Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models. Cancer Biol Ther. 2011 Oct 1;12(7):598-609.

CAS Number

– 779353-01-4

Molecular Weight

– C21H28N6O2

Compound Purity

– 0.9973

SMILES

– N(CC1=CN(=O)=CC=C1)C=2N3C(N=C(C2)N4[C@H](CCO)CCCC4)=C(CC)C=N3

Target

– Others

Pathway

– Apoptosis|||Cell Cycle/Checkpoint

Product type

– Small Compound

Booklet

Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.